Abstract
To the Editor: Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous neuroendocrine malignancy that has been increasing in incidence.1 Four percent to 5% of patients present with unknown primary tumors, which has been observed to be associated with improved overall survival (OS) over those with known primaries.2 To determine the effect of T and M stage on OS, we conducted a retrospective analysis of the National Cancer Database containing patients with lymph node (LN)–positive MCC diagnosed from 2004 to 2016 (Supplementary Fig 1, available via Mendeley at https://doi.org/10.17632/x854j5thxd.2).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
